ASGCT 2026 Abstract Highlights with Emily Walsh Martin, Sanjay D’Souza, and Jason West

Join host Emily Walsh Martin, PhD, as she hands the baton to the new co-hosts of The Issue podcast, Sanjay D’Souza, PhD, and Jason West, PhD. Listen in as the three preview some of the abstracts that will be presented at the ASGCT 2026 Annual Meeting, held May 11-15 in Boston, MA. Music: ‘Bright N…

The Issue – A Caregiver’s Journey from Development to Treatment with Amber Freed, Founder of SLC6A1 Connect

In this episode, host Emily Walsh Martin revisits her 2022 Caregiver’s Perspective interview with Amber Freed, founder of SLC6A1 Connect. Amber is a caregiver to her son Maxwell, who has since received treatment for SLC6A1. Emily and Amber discuss Maxwell’s treatment and the role a caregiver plays …

CGMP iPSC-derived myogenic progenitor product for the treatment of muscular dystrophies with Joseph Glorioso and Rita Perlingeiro

In this episode, Molecular Therapy Editor-in-Chief Dr. Joseph Glorioso and Dr. Rita Perlingeiro (University of Minnesota) will discuss an article recently published in Molecular Therapy titled, “Preclinical quality, safety, and efficacy of a CGMP iPSC-derived myogenic progenitor product for the tre…

The Issue – Prepared under pressure: Navigating the due diligence process with Dr. Ralph Brandenberger

In this episode of The Issue, Emily Walsh Martin is joined by Dr. Ralph Brandenberger, Master Principal; Head of CMC at Dark Horse Consulting for a discussion on due diligence – the most important time in a company’s existence, be it for funding, partnership, or acquisition. Listen in as Ralph and …

mRNA-based CAR T cell engineering with Norman Drzeniek and Niklas Kotzian

Dr. Marcin Kortylewski (Oligonucleotide therapies and applications Section Editor of Molecular Therapy Nucleic Acids) sits down with Dr. Norman Michael Drzeniek and Niklas Kotzian from the Berlin Institute of Health at Charité. Join them as they discuss their new article, mRNA-based CAR T cell engi…

The Issue - Evolving Patient Access to CGTs via Innovation in Medicaid Reimbursement Models with Melissa Majerol

In this episode, Melissa Majerol, Model Lead of the Cell and Gene Therapy Access Model at the Center for Medicare and Medicaid Innovation (CMMI) at CMS, breaks down how the CMMI Access Model program aims to simplify and accelerate patient access to innovative cell and gene therapies, starting with …

Cas9-CLIPT-mediated integration of large transgenes with Krishanu Saha, Anna Tommasi, and Dan Cappabianca

Dr. Daniel Stone (Associate Editor-in-Chief, Molecular Therapy Advances) sits down with Dr. Krishanu Saha, Anna Tommasi, and Dr. Dan Cappabianca from the University of Wisconsin-Madison. Join them as they discuss their team’s recent publication, Efficient nonviral integration of large transgenes in…

RNA interference gene therapy for Parkinson’s disease with Kathy Steece-Collier, Jeffrey Kordower, and Fredric Manfredsson

Molecular Therapy Editor-in-Chief Dr. Joseph Glorioso joins researchers Kathy Steece-Collier (Michigan State University), Jeffrey Kordower (Arizona State University), and Fredric Manfredsson (Barrow Neurological Institute) to discuss their groundbreaking work on RNA interference for Parkinson’s dis…

The Issue - Entrepreneurship, Fundraising, and the Future of Cell & Gene Therapy with Dr. Niki Paulk

Host Dr. Emily Walsh Martin welcomes Dr. Niki Paulk, CEO and Founder of Siren Biotechnology, for a timely conversation on turning scientific promise into commercial success. Dr. Paulk offers perceptive insights into the complex world of biotech entrepreneurship, covering essential fundraising strat…

The Issue - Unlocking New Therapeutic Potential: Ensoma’s Platform for Rare Disease and Oncology

Host Emily Walsh Martin welcomes Dr. Jim Burns, CEO of Ensoma, to discuss the company's novel technological approach to treating both rare diseases and solid tumor oncology. Dr. Burns provides a detailed overview of Ensoma's platform and its application in their ongoing clinical trials, including t…